Physician profile
Eric Ehlenberger
NPI 1518073576
$9,664.95
in general payments reported to CMS, 2019-2025
35 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,368 · 2020: $356 · 2021: $970 · 2022: $908 · 2023: $928 · 2024: $1,625 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,063.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $2,658.58 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $869.27 | 2019-2025 | Relistor |
| Abbvie INC. | $711.47 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $638.13 | 2022-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $625.99 | 2019-2025 | Belbuca, Xtampza |
| Pfizer INC. | $577.32 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $488.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $464.09 | 2021 | |
| Valinor Pharma, LLC | $437.03 | 2023-2025 | Movantik |
| Forte Bio-Pharma LLC | $382.14 | 2020-2024 | Prolate, Nalocet |
| Virtus Pharmaceuticals LLC | $262.42 | 2021-2025 | Levorphanol Tartrate |
| Sentynl Therapeutics, INC. | $214.12 | 2019-2020 | |
| Indivior INC. | $191.81 | 2019-2020 | |
| Protega Pharmaceutials INC | $181.27 | 2025 | Roxybond |
| Idorsia Pharmaceuticals US INC | $173.00 | 2023-2024 | Quviviq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $113.27 | 2023-2024 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $111.52 | 2024-2025 | |
| Zyla Life Sciences, INC. | $110.13 | 2020 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Kaleo, INC. | $65.08 | 2019 | |
| Axsome Therapeutics, INC. | $64.94 | 2025 | Symbravo |
| Appliedvr INC | $30.92 | 2024 | Relievrx |
| Ibsa Pharma INC. | $24.57 | 2025 | Licart, Flector, Tirosint |
| Impel Pharmaceuticals INC. | $22.53 | 2022 | |
| Amgen INC. | $21.28 | 2022 | |
| Grt US Holding, INC. | $19.38 | 2022 | |
| Hikma Pharmaceuticals USA | $18.37 | 2024 | Ryaltris |
| Redhill Biopharma INC. | $17.94 | 2020 | |
| Shionogi INC | $17.09 | 2019 | |
| Novo Nordisk INC | $16.31 | 2023 | Wegovy, Saxenda |
| Lilly USA, LLC | $14.28 | 2021 | |
| Mdd US Operations, LLC | $13.94 | 2019 | |
| Daiichi Sankyo INC. | $11.28 | 2019 | |
| Impel Pharmaceuticals LLC | $6.66 | 2024 | Trudhesa |
| Assertio Therapeutics, INC. | $6.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ehlenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.